New Alzheimer's drug VY7523 enters human trials – could it slow the disease?
Disease control
Ongoing
This study tests a new drug called VY7523 in 52 people with early Alzheimer's disease. The goal is to see if the drug is safe and how it affects the brain. Some participants get the drug, others get a placebo (a dummy treatment). The study lasts up to 12 months and uses brain sca…
Phase: PHASE1, PHASE2 • Sponsor: Voyager Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:38 UTC